Moderna (MRNA) Net Cash Flow (2018 - 2026)

Moderna (MRNA) has 9 years of Net Cash Flow data on file, last reported at -$689.0 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$689.0 million, down 127.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $280.0 million (up 162.92% YoY), and the FY2025 annual result was $666.0 million, up 166.67% from the prior year.
• Net Cash Flow slipped to -$689.0 million in Q1 2026 per MRNA's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.5 billion in Q4 2025 and troughed at -$2.2 billion in Q2 2022.
• A 5-year average of -$291.4 million and a median of -$148.0 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 1450.93% in 2022, then soared 1232.0% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $176.0 million in 2022, then sank by 114.2% to -$25.0 million in 2023, then soared by 1232.0% to $283.0 million in 2024, then jumped by 416.96% to $1.5 billion in 2025, then tumbled by 147.1% to -$689.0 million in 2026.
• Business Quant data shows MRNA's Net Cash Flow at -$689.0 million in Q1 2026, $1.5 billion in Q4 2025, and -$148.0 million in Q3 2025.